- Report
- March 2025
- 1048 Pages
Global
From €4235EUR$4,799USD£3,662GBP
- Report
- November 2024
- 600 Pages
Global
From €2912EUR$3,300USD£2,518GBP
- Report
- August 2025
- 190 Pages
Global
From €3128EUR$3,545USD£2,705GBP
€3476EUR$3,939USD£3,006GBP
- Report
- August 2025
- 196 Pages
Global
From €3128EUR$3,545USD£2,705GBP
€3476EUR$3,939USD£3,006GBP
- Report
- August 2025
- 192 Pages
Global
From €3128EUR$3,545USD£2,705GBP
€3476EUR$3,939USD£3,006GBP
- Report
- August 2025
- 184 Pages
Global
From €3128EUR$3,545USD£2,705GBP
€3476EUR$3,939USD£3,006GBP
- Report
- August 2025
- 189 Pages
Global
From €3128EUR$3,545USD£2,705GBP
€3476EUR$3,939USD£3,006GBP
- Report
- August 2025
- 184 Pages
Global
From €3128EUR$3,545USD£2,705GBP
€3476EUR$3,939USD£3,006GBP
- Report
- August 2025
- 198 Pages
Global
From €3128EUR$3,545USD£2,705GBP
€3476EUR$3,939USD£3,006GBP
- Report
- August 2025
- 199 Pages
Global
From €3128EUR$3,545USD£2,705GBP
€3476EUR$3,939USD£3,006GBP
- Report
- August 2025
- 198 Pages
Global
From €3128EUR$3,545USD£2,705GBP
€3476EUR$3,939USD£3,006GBP
- Report
- August 2025
- 188 Pages
Global
From €3128EUR$3,545USD£2,705GBP
€3476EUR$3,939USD£3,006GBP
- Report
- August 2025
- 187 Pages
Global
From €3128EUR$3,545USD£2,705GBP
€3476EUR$3,939USD£3,006GBP
- Report
- August 2025
- 188 Pages
Global
From €3128EUR$3,545USD£2,705GBP
€3476EUR$3,939USD£3,006GBP
- Report
- August 2025
- 186 Pages
Global
From €3128EUR$3,545USD£2,705GBP
€3476EUR$3,939USD£3,006GBP
- Report
- August 2025
- 184 Pages
Global
From €3128EUR$3,545USD£2,705GBP
€3476EUR$3,939USD£3,006GBP
- Report
- August 2025
- 181 Pages
Global
From €3128EUR$3,545USD£2,705GBP
€3476EUR$3,939USD£3,006GBP
- Report
- August 2025
- 197 Pages
Global
From €3128EUR$3,545USD£2,705GBP
€3476EUR$3,939USD£3,006GBP
- Report
- March 2025
- 150 Pages
Global
From €3397EUR$3,850USD£2,938GBP
€4280EUR$4,850USD£3,701GBP
- Report
- April 2025
- 250 Pages
Global
From €3962EUR$4,490USD£3,427GBP

The Neoantigen market is a subset of the Genomics market that focuses on the identification and development of neoantigens for use in cancer immunotherapy. Neoantigens are proteins that are produced by tumor cells and are recognized by the immune system as foreign, triggering an immune response. By targeting these neoantigens, cancer immunotherapy can be used to treat cancer. Companies in the Neoantigen market are focused on developing technologies to identify and develop neoantigens for use in cancer immunotherapy.
Companies in the Neoantigen market include Adaptive Biotechnologies, I-Mab, Neoantigen Therapeutics, NeoVax, and OncoImmune. Show Less Read more